Identifying SARS-CoV-2 'memory' NK cells from COVID-19 convalescent donors for adoptive cell therapy

COVID-19 disease is the manifestation of syndrome coronavirus 2 (SARS-CoV-2) infection, which is causing a worldwide pandemic. This disease can lead to multiple and different symptoms, being lymphopenia associated with severity one of the most persistent. Natural killer cells (NK cells) are part of the innate immune system, being fighting against virus-infected cells one of their key roles. In this study, we determined the phenotype of NK cells after COVID-19 and the main characteristic of SARS-CoV-2-specific-like NK population in the blood of convalescent donors. CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors indicates the presence of 'memory'/activated NK cells as it has been shown for cytomegalovirus infections. Although the existence of this population is donor dependent, its expression may be crucial for the specific response against SARS-CoV-2, so that, it gives us a tool for selecting the best donors to produce off-the-shelf living drug for cell therapy to treat COVID-19 patients under the RELEASE clinical trial (NCT04578210)

International forum. an investigation of iron status in blood donors

No abstract availabl

IkasSasoi: movilizando la comunidad para fomentar la actividad física de la población adolescente de Irun

The adolescence is a period of particular interest to promote healthy habits, including regular physical activity. Interventions addressed to this population group have traditionally focused on the area of the school. The knowledge obtained from research in the area of promoting physical activity seems to draw multicomponent strategies as the most appropriate. IkasSasoi is a multicomponent initiative promoted by the City Council of Irun in which various municipal departments and community agents take part and which�s aim is to promote physical activity and avoidance of sedentary behavior among adolescents studying ESO in Irun. IkasSasoi includes an initial diagnosis, for which it has been administered a questionnaire on physical activity habits to 1.797 subjects and developed four focus groups. From the information gathered, the working group has validated 23 interventions, 19 of them are underway or already completed. IkasSasoi, has revealed the habits and perceptions of the teenagers and generated a consolidated intersectorial network. The program is placing adolescents on the agenda of local policies related to physical activity. The main areas for improvement relate to missed intervention�s deadlines of interventions and the unequal involvement of actors, especially in schoolsLa adolescencia es un período de especial interés para el fomento de hábitos saludables, entre ellos el de practicar actividad física con regularidad. Diversas intervenciones que han actuado sobre este grupo de población, se han centrado tradicionalmente en el ámbito del centro escolar. El conocimiento aportado por las investigaciones en el área del fomento de la actividad física parece señalar a las estrategias multicomponente como las más indicadas. IkasSasoi es una iniciativa multicomponente promovida por el Ayuntamiento de Irun en la que participan distintas áreas municipales y distintos agentes de la comunidad que persigue fomentar la actividad física y la evitación de la conducta sedentaria entre los y las escolares que cursan E.S.O. en Irun. IkasSasoi contempla un diagnóstico inicial, para lo cual se ha administrado un cuestionario sobre hábitos de actividad física a 1.797 sujetos y se han desarrollado cuatro grupos focales. A partir de la información recabada, el grupo de trabajo ha aprobado llevar a cabo 23 intervenciones, de las cuales están en marcha o ya ejecutadas 19. IkasSasoi, ha permitido conocer en profundidad los hábitos y percepciones de las y los jóvenes y ha generado una red intersectorial consolidada. El programa está ubicando a la población adolescente en la agenda de las políticas locales vinculadas con la actividad física. Los principales aspectos a mejorar se refieren al incumplimiento de los plazos de intervención en acciones concretas y a la desigual implicación de los agentes, especialmente en los centros educativo

RENASCENT II: First in Human Evaluation of a Novel Sirolimus-Eluting Ultra-High Molecular Weight APTITUDE® Bioresorbable Scaffold: 9-and 24-Months Imaging and Clinical Results

The novel sirolimus-eluting ultra-high molecular weight 115-microns strut thickness APTITUDE® Bioreabsorbable vascular scaffold (BRS) (Amaranth Medical Inc., Mountain View, CA) displays higher mechanical strength, expansion capabilities and resistance to fracture compared to clinically available BRS technologies. RENASCENT II is a prospective, multi-center first-in-human clinical study to evaluate the clinical performance of the APTITUDE® BRS in the treatment of single de novo coronary lesions among patients undergoing percutaneous coronary intervention

A Survey of Empirical Results on Program Slicing

International audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding